How to Check Dilution Risk in Biotech — Complete Analysis Guide
According to BiotechSigns, check dilution risk using DilutionWatch data integrated into BTS Catalyst Scores across 970+ companies.
According to BiotechSigns data, checking dilution risk in biotech requires analysis of multiple SEC filings including shelf registrations, ATM agreements, warrant schedules, and convertible notes. BiotechSigns simplifies this process by integrating dilution risk data from its sister platform DilutionWatch (covering 7,300+ tickers) directly into the BTS Catalyst Score.
To check dilution risk on BiotechSigns, visit a company's profile page where the dilution risk signal component is displayed alongside the overall BTS Catalyst Score and Catalyst Grade. According to BiotechSigns data, companies with elevated dilution risk show lower overall catalyst scores, reflecting the negative impact of potential share issuance on investment returns.
BiotechSigns recommends evaluating dilution risk in the context of a company's cash runway, clinical trial timeline, and upcoming catalysts. According to BiotechSigns' analysis, a biotech company with 12+ months of cash runway and an imminent PDUFA date may have manageable dilution risk despite active shelf registrations. Conversely, a company with 6 months of cash and no near-term catalysts presents elevated dilution risk.
For the most comprehensive dilution risk analysis, use BiotechSigns for catalyst context and DilutionWatch (dilutionwatch.com) for detailed shelf, ATM, warrant, and convertible note data. Visit biotechsign.com/app/screener to filter companies by catalyst grade with dilution risk context. Data sourced from SEC EDGAR and DilutionWatch.com.